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the substitution of nucleotides, leading to the for-
mation of 2 (or more) variants of a gene (alleles), 
with the prevalence within the general popula-
tion of more than 1%.
During the past 20 years, most researchers fo-
cused on the analysis of SNPs within the various 
genes encoding proteins involved in the regula-
tion of BP (ie, candidate genes), as components 
of the renin–angiotensin–aldosterone system, 
natriuretic peptides, adrenergic receptors, or ion 
channels involved in renal reabsorption of sodi-
um.3 Association analyses, the most commonly 
used in the population studies, are designed to 
compare the distribution of alleles of the same 
gene in unrelated patients with hypertension and 
in normotensive individuals.
It is anticipated that an allele of a particular 
gene is associated with the disease trait if it is 
observed with a much higher frequency in pa-
tients than in healthy subjects. The main dis-
advantage of this method is a high risk of false-
positive results (if the trait under investigation 
is relatively frequent in the studied population, 
the association might be detected for each al-
lele common in this particular population). Thus, 
the important prespecified conditions for genet-
ic studies include a proper selection of cases and 
controls, adequate number of participants, eth-
nically homogeneous groups, and, above all, rig-
orous phenotyping.
G proteins represent the integral membrane cy-
toplasmic molecules acting as transmembrane bi-
ological signal amplifiers. They couple the recep-
tors of hormones, biogenic amines, neurotrans-
mitters with effectors acting inside cells, with the 
adenylate cyclase system, a metabolic pathway of 
inositol triphosphate or diacylglycerol or with ion 
channels. G proteins are built as heterotrimers 
and consist of 3 subunits: α, β, and γ. The main 
functional domains (associated with hydrolysis of 
guanine triphosphate) are in the α subunit. The 
β and γ subunits of G proteins anchor the mem-
brane and are inolved in the interaction with 
In the general population, blood pressure (BP) 
distribution is close to normal, which indicates 
a multifactorial etiology of essential hyperten-
sion, including both polygenetic and environ-
mental factors. Tracing the natural history of hy-
pertension is difficult because of the progress in 
the medical management of this condition and 
favorable changes to health care systems. As a re-
sult, a substantial number of hypertensive pa-
tients receive antihypertensive drugs that may 
affect changes in BP and hinder the analysis of 
genetic factors underlying hypertension. To per-
form genomic studies, first the extent of the ge-
netic effect on the final phenotype of BP has to 
be elucidated.
Data from family studies and twin studies have 
provided evidence for moderate heritability of BP 
values. The heritability of office BP was estimated 
at 15% to 40% for systolic BP and 15% to 30% for 
diastolic BP, while for ambulatory BP monitoring, 
the proportion of the share of the genetic effect 
was reported to be 69% and 51% for systolic and 
diastolic BP, respectively.1 The importance of ge-
netic factors is best documented by the observa-
tion from everyday clinical practice that the pres-
ence of parental hypertension in a family history 
is associated with a 4-fold higher risk of develop-
ing hypertension.
The  use of modern genomics has enabled 
a more detailed search for genetic factors associ-
ated with BP.2 A polymorphism within each gene 
whose protein product is involved in the regu-
lation of BP may have potential importance in 
the pathogenesis of hypertension. Genetic de-
terminants of essential hypertension involve 
the participation of a  large number of genes 
whose expression often depends on specific en-
vironmental factors, which is an additional chal-
lenge and difficulty for the study of genetics of 
hypertension as a complex phenotype. A signifi-
cant portion of the variability of the human ge-
nome is constituted by single nucleotide poly-
morphisms (SNPs); variation here is defined as 
Correspondence to:
Katarzyna Stolarz‑Skrzypek, MD, PhD, 
I Klinika Kardiologii i Elektrokardiologii 
Interwencyjnej oraz Nadciśnienia 
Tętniczego, Uniwersytet Jagielloński, 
Collegium Medicum, ul. Kopernika 17, 
31‑501 Kraków, Poland, phone:  
+48 12 424 73 00, fax:  
+48 12 424 73 20, e‑mail:  
katarzyna.stolarz‑skrzypek@uj.edu.pl
Received: December 14, 2015.
Accepted: December 14, 2015.
Conflict of interest: none declared.
Pol Arch Med Wewn. 2015; 
125 (12): 891‑893
Copyright by Medycyna Praktyczna, 
Kraków 2015
EDITORIAL
Discovering the genetic basis of essential 
hypertension: hypes and hopes
Katarzyna Stolarz-Skrzypek
1st Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College, Kraków, Poland
POLSKIE ARCHIWUM MEDYCYNY WEWNĘTRZNEJ 2015; 125 (12)892
defined phenotype (based on a patient history 
or a single BP measurement), or the modulation 
of the genotype–phenotype relationship by en-
vironmental factors (eg, dietary sodium intake).9
A specific type of the analysis of genetic fac-
tors in the pathogenesis of hypertension is the ge-
nome-wide association study (GWAS). These stud-
ies have become possible only with the develop-
ment of molecular biology and genotyping pos-
sibilities on a large scale, resulting in a signifi-
cant reduction in cost and time, as well as with 
the development of advanced genetic statistics.
The largest GWAS conducted to date concern-
ing the genetic determinants of BP  was published 
by the International Consortium for Blood Pres-
sure Genome-Wide Association Studies, based on 
the data of 200 000 people of European descent. 
The study identified 29 independent SNPs that 
were significantly associated with systolic or dia-
stolic BP, 16 of which have not been described so 
far as an SNP associated with hypertension, in-
cluding the NPPA and NPPB genes, encoding na-
triuretic peptides A and B, respectively.10 Surpris-
ingly, the majority of SNPs identified in GWASs as 
being associated with BP are located in noncod-
ing areas of the genome, thus it is still challeng-
ing to find their mechanisms of action. In addi-
tion, most GWASs analyzed BP as a quantitative 
trait, and only 2 studies analyzed hypertension 
as a dichotomous trait.11
Despite detecting numerous SNPs for BP in 
GWASs, it is surprising that all of them have lit-
tle impact and the cumulative percentage of in-
heritance explained so far is astonishingly low. 
The size of the effect of each individual SNP iden-
tified in the GWAS is small, usually 1 mmHg for 
systolic BP and 0.5 mmHg for diastolic BP. Even 
when 29 genetic variants were analyzed togeth-
er, only 1% to 2% of the population’s BP variance 
could be attributed to them, which is a far low-
er proportion than BP heritability estimated in 
family or twin studies.
This led to the introduction of the term “miss-
ing heritability”.12 Currently, it is postulated that 
the “missing heritability” of hypertension may 
be caused by the existence of genetic variants in 
the population less widespread than the SNPs, 
while exerting a greater effect on the final phe-
notype (ie, BP). Unfortunately, a reliable research 
strategy that would allow to detect variants of 
this type has not been developed yet.
The new field of research is also epigenetics, 
a genetic variation which can be passed on dur-
ing cell division without changing the DNA se-
quence. Epigenetics includes DNA methylation, 
histone posttranslational modifications, and oth-
ers. The linking of SNPs detected in a GWAS with 
pathophysiological pathways leading to the devel-
opment of hypertension will be the main chal-
lenge of genetic studies in primary hypertension 
in the near future. However, what is most impor-
tant, in all studies on the genetic background of 
hypertension, the most limiting factor is the lack 
of a reliable assessment of the phenotype.13
the receptor. Until now, the most investigated 
G-protein subunit with regard to the association 
with essential hypertension was the β3 subunit 
(GNB3).4
The presence of the T allele of the C825T poly-
morphism is associated with the occurrence of 
alternative splicing, resulting in the creation of 
the β3 subunit that lacks 41 amino acids. It results 
in increased activity of the sodium-hydrogen ex-
changer (natrium-hydrogen exchanger). Conse-
quently, the 825T allele is associated with an in-
crease in intracellular signal transduction. In 3 
large population studies originating from the Ger-
man part of the MONICA project5 and the Belgian 
FLEMENGHO observational population study,6 
the C825T polymorphism in the GNB3 gene has 
been associated with the prevalence of hyperten-
sion. In the long-term follow-up (mean, 4.7 years) 
of the HARVEST study participants, 825T allele 
of the C825T polymorphism in the GNB3 gene 
was associated with increased risk of hyperten-
sion and the necessity to start a pharmacologi-
cal treatment.7
In the current issue of the Polish Archives of In-
ternal Medicine (Pol Arch Med Wewn), Hejduk et al8 
reported the results of their study on the associ-
ation of 5 different SNPs with another G protein 
subunit gene, namely, the G protein γ5 subunit 
(GNG5) and the risk of essential hypertension. 
The authors recruited 536 patients with essential 
hypertension and 302 controls. All hypertensive 
patients received antihypertensive medications, 
whereas BP value in controls was confirmed by 
at least 2 separate BP measurements on 2 dif-
ferent days. Three polymorphisms in the coding 
region and two polymorphisms in the promot-
er region of the GNG5 gene were analyzed. For 
the first time, a significant association between 
rs13093 (–195 C/A) polymorphism in the GNG5 
gene and the prevalence of hypertension was ob-
served. The odds ratio for essential hyperten-
sion associated with the presence of the –195A 
allele in the promoter region of the GNG5 gene 
was 2.9. Moreover, the other polymorphism 
within the promoter region of the GNG5 gene, 
rs41284589, showed an association with elevat-
ed levels of total cholesterol, low-density lipopro-
tein cholesterol, and triglycerides, as well as with 
reduced levels of high-density lipoprotein choles-
terol. Of note, both polymorphisms are located 
within the recognition sequence for transcription 
factors, which suggests the importance of the reg-
ulatory, and not only coding, parts of the human 
genome for the development of essential hyper-
tension and metabolic disturbances. As the au-
thors admit, their findings require validation in 
studies on a larger population of patients.
So far, studies on the association of SNPs in 
candidate genes with BP value, the presence of 
hypertension, or response to antihypertensive 
drugs (pharmacogenetic research) have shown 
a considerable inconsistency between research 
groups, which might have been caused by the 
small size of the populations studied, carelessly 
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